Decreased DHRS2 expression is associated with HDACi resistance and poor prognosis in ovarian cancer

References

• Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011;61:183–203.
   PubMed Web of Science ®Google Scholar
• Damia G, Broggini M. Platinum Resistance in Ovarian Cancer: Role of DNA Repair. Cancers (Basel). 2019;11(1):119.
   Google Scholar
• Natanzon Y, Goode EL, Cunningham JM. Epigenetics in ovarian cancer. Semin Cancer Biol. 2018;51:160–169.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med. 2011;17:330–339.
   PubMed Web of Science ®Google Scholar
• Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol. 2007;25:84–90.
   PubMed Web of Science ®Google Scholar
• Roche J, Bertrand P. Inside HDACs with more selective HDAC inhibitors. Eur J Med Chem. 2016;121:451–483.
   PubMed Web of Science ®Google Scholar
• Singh AK, Bishayee A, Pandey AK. Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy. Nutrients. 2018;10(6):731.
   Web of Science ®Google Scholar
• Qiu X, Xiao X, Li N, et al. Histone deacetylases inhibitors (HDACis) as novel therapeutic application in various clinical diseases. Prog Neuropsychopharmacol Biol Psychiatry. 2017;72:60–72.
   PubMed Web of Science ®Google Scholar
• Muscolini M, Cianfrocca R, Sajeva A, et al. Trichostatin A up-regulates p73 and induces Bax-dependent apoptosis in cisplatin-resistant ovarian cancer cells. Mol Cancer Ther. 2008;7:1410–1419.
   PubMed Web of Science ®Google Scholar
• Sonnemann J, Gange J, Pilz S, et al. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients. BMC Cancer. 2006;6:183.
   PubMed Web of Science ®Google Scholar
• Khabele D. The therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancer. Front Oncol. 2014;4:111.
   PubMedGoogle Scholar
• Moufarrij S, Dandapani M, Arthofer E, et al. Epigenetic therapy for ovarian cancer: promise and progress. Clin Epigenetics. 2019;11:7.
   PubMed Web of Science ®Google Scholar
• Han Y, Sun S, Zhao M, et al. CYC1 Predicts Poor Prognosis in Patients with Breast Cancer. Dis Markers. 2016;2016:3528064.
   PubMedGoogle Scholar
• Taylor PT, Haverstick D. Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst. 2005;97:151. author reply 2
   PubMedGoogle Scholar
• Ji T, Gong D, Han Z, et al. Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer. Cancer Lett. 2013;341:231–239.
   PubMed Web of Science ®Google Scholar
• Koeneke E, Witt O, Oehme I. HDAC family members intertwined in the regulation of autophagy: a druggable vulnerability in aggressive tumor entities. Cells. 2015;4:135–168.
   PubMed Web of Science ®Google Scholar
• Gyorffy B, Lanczky A, Szallasi Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer. 2012;19:197–208.
   PubMed Web of Science ®Google Scholar
• Lamb J, Crawford ED, Peck D, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313:1929–1935.
   PubMed Web of Science ®Google Scholar
• Ushijima M, Mashima T, Tomida A, et al. Development of a gene expression database and related analysis programs for evaluation of anticancer compounds. Cancer Sci. 2013;104:360–368.
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1.
   PubMed Web of Science ®Google Scholar
• Basu A, Bodycombe NE, Cheah JH, et al. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell. 2013;154:1151–1161.
   PubMed Web of Science ®Google Scholar
• Zagni C, Floresta G, Monciino G, et al. The search for potent, small-molecule HDACIs in cancer treatment: a decade after vorinostat. Med Res Rev. 2017;37:1373–1428.
   PubMed Web of Science ®Google Scholar
• Labisso WL, Wirth M, Stojanovic N, et al. MYC directs transcription of MCL1 and eIF4E genes to control sensitivity of gastric cancer cells toward HDAC inhibitors. Cell Cycle. 2012;11:1593–1602.
   PubMed Web of Science ®Google Scholar
• Tan TZ, Yang H, Ye J, et al. CSIOVDB: a microarray gene expression database of epithelial ovarian cancer subtype. Oncotarget. 2015;6:43843–43852.
   PubMedGoogle Scholar
• Li Y, Seto E. HDACs and HDAC Inhibitors in Cancer Development and Therapy. Cold Spring Harb Perspect Med. 2016;6(10).
   Web of Science ®Google Scholar
• Nemati M, Ajami N, Estiar MA, et al. Deregulated expression of HDAC3 in colorectal cancer and its clinical significance. Adv Clin Exp Med. 2018;27:305–311.
   PubMed Web of Science ®Google Scholar
• Miyake K, Yoshizumi T, Imura S, et al. Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation. Pancreas. 2008;36:e1–9.
   PubMed Web of Science ®Google Scholar
• Higashijima J, Kurita N, Miyatani T, et al. Expression of histone deacetylase 1 and metastasis-associated protein 1 as prognostic factors in colon cancer. Oncol Rep. 2011;26:343–348.
   PubMed Web of Science ®Google Scholar
• Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25:3109–3115.
   PubMed Web of Science ®Google Scholar
• Manal M, Chandrasekar MJ, Gomathi Priya J, et al. Inhibitors of histone deacetylase as antitumor agents: A critical review. Bioorg Chem. 2016;67:18–42.
   PubMed Web of Science ®Google Scholar
• Rees MG, Seashore-Ludlow B, Cheah JH, et al. Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nat Chem Biol. 2016;12:109–116.
   PubMed Web of Science ®Google Scholar
• Suganya N, Bhakkiyalakshmi E, Subin TS, et al. Proteomic identification of pterostilbene-mediated anticancer activities in HepG2 cells. Chem Res Toxicol. 2014;27:1243–1252.
   PubMed Web of Science ®Google Scholar
• Song J, Shih Ie M, Chan DW, et al. Suppression of annexin A11 in ovarian cancer: implications in chemoresistance. Neoplasia. 2009;11: 605–614. 1 p following 14.
   PubMed Web of Science ®Google Scholar
• Okochi-Takada E, Nakazawa K, Wakabayashi M, et al. Silencing of the UCHL1 gene in human colorectal and ovarian cancers. Int J Cancer. 2006;119:1338–1344.
   PubMed Web of Science ®Google Scholar
• Petropavlovskaia M, Bodnar CA, Behie LA, et al. Pancreatic small cells: analysis of quiescence, long-term maintenance and insulin expression in vitro. Exp Cell Res. 2007;313:931–942.
   PubMed Web of Science ®Google Scholar
• Deisenroth C, Thorner AR, Enomoto T, et al. Mitochondrial Hep27 is a c-Myb target gene that inhibits Mdm2 and stabilizes p53. Mol Cell Biol. 2010;30:3981–3993.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Wang L, Ban X, et al. DHRS2 inhibits cell growth and motility in esophageal squamous cell carcinoma. Oncogene. 2018;37:1086–1094.
   PubMed Web of Science ®Google Scholar
• Han Y, Song C, Wang J, et al. HOXA13 contributes to gastric carcinogenesis through DHRS2 interacting with MDM2 and confers 5-FU resistance by a p53-dependent pathway. Mol Carcinog. 2018;57:722–734.
   PubMed Web of Science ®Google Scholar